Asymptomatic Elevation of Amylase and Lipase After Olanzapine Treatment

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F16%3A00065621" target="_blank" >RIV/65269705:_____/16:00065621 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14740/16:00090599
Result on the web
<a href="http://dx.doi.org/10.1097/JCP.0000000000000460" target="_blank" >http://dx.doi.org/10.1097/JCP.0000000000000460</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/JCP.0000000000000460" target="_blank" >10.1097/JCP.0000000000000460</a>

Result language
angličtina
Original language name
Asymptomatic Elevation of Amylase and Lipase After Olanzapine Treatment
Original language description
Olanzapine, an atypical antipsychotic,has been considered one of the most efficient antipsychotic drugs, and it is the most frequently prescribed. It is categorized as a multiacting receptor targeted antipsychotic. The most significant adverse effects of olanzapine are metabolic: acute pancreatitis is one of the most serious adverse effects; fortunately, it does not occur very often. Koller et al1 found 51 cases,and at least 13 cases have been described more precisely. We present a case study of a young female patient with a very fast and high increase of amylase and lipase, who remained asymptomatic, immediately after olanzapine treatment.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FR - Pharmacology and apothecary chemistry
OECD FORD branch
—

Project
<a href="/en/project/LQ1601" target="_blank" >LQ1601: CEITEC 2020</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)